Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.

Clinical Drug Investigation
Keiko OgawaRumiko Hosoki

Abstract

Immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors have greatly improved cancer treatment. However, they are associated with immune-related adverse events, including autoimmune diseases (ADs) owing to their immune enhancement effect. As there are few comprehensive studies of ADs by ICIs, it is necessary to analyze the period information of drug-induced ADs. We also assumed that the temporal information may be useful to estimate the similarity of the pathogenic mechanism between spontaneous and ICI-induced ADs. A period analysis including the Weibull analysis was performed on ICI-induced ADs using the Japanese Adverse Drug Event Report (JADER) database. For evaluating the similarity of spontaneous and ICI-induced ADs, a hierarchical cluster analysis was conducted to compare the different onset-time ranges. Type 1 diabetes mellitus, autoimmune colitis, and pemphigoid occurred earlier with CTLA-4 inhibitors (median: 46, 29.5 and 28 days, respectively) than with PD-1 inhibitors (> 130 days). Myasthenia gravis had a median time to onset of approximately 1 month, and the risk of onset would increase over time in ipilimumab combination therapy. Th...Continue Reading

References

Jul 1, 1989·Japanese Journal of Medicine·M NobunagaM Shingu
Jul 3, 1998·Diabetes Research and Clinical Practice·H YamadaY Iwamoto
Jul 9, 2003·The Journal of Experimental Medicine·Mohammed Javeed I AnsariMohamed H Sayegh
Aug 19, 2004·Pharmacoepidemiology and Drug Safety·Kenneth J RothmanSusan T Sacks
Apr 22, 2006·Pancreas·Isao NishimoriUNKNOWN Research Committee on Intractable Pancreatic Diseases, the Ministry of Health and Welfare of Japan
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Sep 2, 2008·Immunological Reviews·Brian T Fife, Jeffrey A Bluestone
May 29, 2009·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Y MiyakeK Yamamoto
Nov 16, 2010·Journal of Neuroimmunology·Shigeaki SuzukiNorihiro Suzuki
Dec 24, 2011·Autoimmune Diseases·Manuel J Amador-PatarroyoGladis Montoya-Ortiz
Jun 19, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Victoria R CorneliusStephen J W Evans
May 16, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Odile SauzetVictoria R Cornelius
Sep 3, 2013·Lancet·Marie Wahren-Herlenius, Thomas Dörner
May 6, 2014·Frontiers in Neuroendocrinology·S T NgoP A McCombe
Jun 5, 2014·Journal of Biopharmaceutical Statistics·Jianrong Wu
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Jan 5, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Eiji KoseHiroyuki Hayashi
Feb 17, 2017·International Journal of Rheumatic Diseases·Eri KatoShigeto Tohma
Jul 1, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D MakariousJ I G Coward
Nov 23, 2017·Journal for Immunotherapy of Cancer·I PuzanovUNKNOWN Society for Immunotherapy of Cancer Toxicity Management Working Group
Dec 5, 2017·Biological & Pharmaceutical Bulletin·Satoshi NakaoMitsuhiro Nakamura
Mar 22, 2018·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 214 Investigators
Mar 24, 2018·Science·Antoni Ribas, Jedd D Wolchok
Apr 10, 2018·Autoimmunity Reviews·Milena TocutGisele Zandman-Goddard
Jun 29, 2018·Journal of Gastroenterology·Hiroyuki IsayamaUNKNOWN PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobili
Jun 30, 2018·The Journal of Clinical Endocrinology and Metabolism·Katrien ClotmanChristophe E M De Block
Dec 7, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Fusao KomadaKohji Takara
Feb 26, 2019·Diabetology International·Megu Yamaguchi BadenUNKNOWN consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research
Aug 23, 2019·JAMA Oncology·Yoshito ZamamiKeisuke Ishizawa
Sep 29, 2019·The New England Journal of Medicine·Matthew D HellmannSuresh S Ramalingam
Sep 29, 2019·The New England Journal of Medicine·James LarkinJedd D Wolchok
Nov 7, 2019·Biological & Pharmaceutical Bulletin·Go AndoKazuaki Matsumoto
Nov 30, 2019·Current Oncology Reports·Peter Chei-Way Pan, Aya Haggiagi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Canadian Medical Association Journal
The Journal of the American Dental Association
R H Scholle
The New England Journal of Medicine
J D Youman
© 2021 Meta ULC. All rights reserved